Weant, E. H., Woodring, S., Randazzo, D., Friedman, H., Desjardins, A., Vlahovic, G., … Afrronti, M. L. (n.d.). Randomized open-label phase II tril of aprepitant plus ondansetron compared to ondansetron alone in prevention of chemotherapy-induced-nausea-vomiting (CINV) in glioma patients receiving adjuvant temozolomide. In Supportive Care in Cancer (Vol. 25, pp. S128–S128). Washington, DC: Springer (part of Springer Nature). https://doi.org/10.1007/s00520-017-3704-x

Weant, Erin H., Sarah Woodring, Din Randazzo, Henry Friedman, Annick Desjardins, Gordana Vlahovic, Patrick Healy, et al. “Randomized open-label phase II tril of aprepitant plus ondansetron compared to ondansetron alone in prevention of chemotherapy-induced-nausea-vomiting (CINV) in glioma patients receiving adjuvant temozolomide.” In Supportive Care in Cancer, 25:S128–S128. Springer (part of Springer Nature), n.d. https://doi.org/10.1007/s00520-017-3704-x.

Weant EH, Woodring S, Randazzo D, Friedman H, Desjardins A, Vlahovic G, et al. Randomized open-label phase II tril of aprepitant plus ondansetron compared to ondansetron alone in prevention of chemotherapy-induced-nausea-vomiting (CINV) in glioma patients receiving adjuvant temozolomide. In: Supportive Care in Cancer. Springer (part of Springer Nature); p. S128–S128.

Weant, Erin H., et al. “Randomized open-label phase II tril of aprepitant plus ondansetron compared to ondansetron alone in prevention of chemotherapy-induced-nausea-vomiting (CINV) in glioma patients receiving adjuvant temozolomide.” Supportive Care in Cancer, vol. 25, no. 2, Springer (part of Springer Nature), pp. S128–S128. Manual, doi:10.1007/s00520-017-3704-x.

Weant EH, Woodring S, Randazzo D, Friedman H, Desjardins A, Vlahovic G, Healy P, Herndon J, McSherry F, Lipp E, Miller E, Cone C, Kim J-Y, Southerland C, Brown C, Carter M, Johnson MO, Peters K, Afrronti ML. Randomized open-label phase II tril of aprepitant plus ondansetron compared to ondansetron alone in prevention of chemotherapy-induced-nausea-vomiting (CINV) in glioma patients receiving adjuvant temozolomide. Supportive Care in Cancer. Springer (part of Springer Nature); p. S128–S128.